Canaan Inc. has reported a significant surge in revenue and operational performance in its unaudited Q4 2025 financial statements.

Sales hit a new record in 2022 and are expected to increase by a further 10.12% in 2023. Both gross profit and EBITDA margins have significantly improved in recent quarters thanks to an easing of ...

Royalty Pharma delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions. The company increased its dividend per share by 5% and reported adjusted cash receipts ...